What is the main business of Valueadd Pharma (By Dr. Murpani)?

The main business activity of Valueadd Pharma (By Dr. Murpani) focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 7, 2017.

Where is the headquarters located?

The headquarters is located at: ul. Domaniewska 47, 02-672 Warszawa.

What is the legal form?

The legal form of this entity is a limited partnership (sp.k.).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $220,817, representing a decrease of 9.1% compared to 2024.

Yes, the company recorded a net profit of $176,109 in 2025, meaning the company decreased its profit by 18.7%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $3,389 in 2025, representing 63% of all operating expenses.

Valueadd Pharma (By Dr. Murpani)sp. k.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2017-03-07

Registered address

ul. Domaniewska 47/10, 02-672 Warszawa, Poland

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 98 days early.

202502/04/2026
202419/03/2025
202311/03/2024
202228/02/2023
202127/04/2022
201923/09/2020

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 220.82kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD 176.11kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 5.36kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 184.73kMedianUSD 133.19kAverageUSD 3.03m

Industry

Partners

Partners	Partner role
Deepak Kumar Murpaniage 54	General partner
Valueadd Pharma sp. z o.o.	General partner

Manner of representation

The general partner is entitled to represent the company independently vis-à-vis third parties.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2017-04-01.

ING Bank Śląski
13 1050 1012 1000 0090 3123 5519
ING Bank Śląski
62 1050 1012 1000 0024 4033 0047
ING Bank Śląski
88 1050 1012 1000 0090 3123 5527

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$152$152	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$152$152	Prezes Zakładu Ubezpieczeń Społecznych
May 3, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$152$152	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

Name	Revenue	Website
Medicofarma BiotechS.A.	$314,882.33	medicofarmabiotech.pl
Explorna Therapeuticssp. z o.o.	$304,662.00	explorna.com
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Bioselsp. z o.o.	$19,100.32	selol.pl